HCPCS J7634: Budesonide Inhalation Solution, Compounded, DME

HCPCS Level II code J7634 represents a compounded budesonide inhalation solution in concentrated form, billed per 0.25 milligram and intended for administration via durable medical equipment (nebulizer). This code matters nationally because it governs billing for compounded inhaled corticosteroid therapy delivered through DME, a common modality for patients with respiratory conditions who require home or outpatient nebulized treatment.

Key payers covered in this analysis include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find a concise overview of the clinical context for nebulized budesonide, the typical sites of service, and which payers are relevant to coverage and reimbursement discussions. The publication summarizes benchmarks where available, highlights notable policy considerations for compounded inhalation products administered through DME, and provides context on coding practice for this HCPCS Level II medication code.

The report is intended to inform billing, revenue cycle, and policy teams about the coding implications and administrative considerations tied to J7634, including how the code aligns with outpatient and home-based nebulizer therapy and the types of documentation that commonly accompany claims for compounded inhalation solutions.

Billing Code Overview

HCPCS Level II code J7634 describes budesonide, inhalation solution, compounded product, administered through durable medical equipment (DME), concentrated form, per 0.25 milligram. This code represents a compounded inhalation corticosteroid formulation intended for nebulized delivery.

Service type: Medication administration via DME (nebulized inhalation solution)
Typical site of service: Home or outpatient settings where durable medical equipment (nebulizer) is used for inhalation therapy

Data not available in the input.

Clinical Context

A typical patient is an adult or pediatric patient with persistent asthma or corticosteroid-responsive airway inflammation who requires inhaled corticosteroid therapy delivered via a durable medical device (nebulizer). The compounded concentrated budesonide inhalation solution (J7634) is prepared by a pharmacy and administered through DME (nebulizer) in an outpatient infusion suite, office-based pulmonary clinic, home health setting, or skilled nursing facility when unit-dose or premixed products are not available or a custom concentration is required.

A realistic workflow: a pulmonologist documents uncontrolled asthma despite inhaler therapy and prescribes a compounded budesonide inhalation solution at a specific concentration. The prescription is sent to a compounding pharmacy which prepares the concentrated product per physician order; the pharmacy dispenses and bills for the compound while the treating facility or DME supplier documents administration through the nebulizer. Clinical monitoring includes baseline vitals and spirometry when performed, instruction on nebulizer use, observation for acute adverse effects (bronchospasm, hypersensitivity), and follow-up visits to assess symptom control and need for continued therapy.

Coding Specifications

Modifier	Description	When to Use
`00`	No modifier	Use when no specific modifier applies to the service

Taxonomy Code	Specialty	Notes
`207RP1000X`	Pulmonary Disease	Pulmonologists commonly prescribe and manage inhaled corticosteroid therapy
`207L00000X`	Allergy & Immunology	Allergists manage steroid-responsive airway diseases and may prescribe compounded inhaled steroids
`207Q00000X`	Pediatric Pulmonology	Pediatric pulmonologists manage children requiring nebulized budesonide
`363LP0200X`	Pharmacy	Compounding pharmacists prepare the concentrated solution and ensure sterility and correct dosing
`362500000X`	Nursing	Home health or infusion nurses may administer and monitor nebulized therapy

Related Diagnoses

ICD-10 Code	Description	Clinical Relevance
`J45.40`	Moderate persistent asthma, uncomplicated	Common indication for inhaled corticosteroid therapy delivered via nebulizer
`J45.30`	Mild persistent asthma, uncomplicated	Nebulized budesonide may be used when inhaler technique is inadequate or during exacerbations
`J45.901`	Unspecified asthma with (acute) exacerbation	Nebulized corticosteroids can be used as part of exacerbation management
`J96.00`	Acute respiratory failure, unspecified whether with hypoxia or hypercapnia	In select settings nebulized steroids may be part of broader respiratory management
`R06.02`	Shortness of breath	Symptom prompting nebulized bronchodilator and corticosteroid therapy
`J98.01`	Acute bronchospasm	Nebulized therapy is used to reduce bronchospasm and airway inflammation
`J45.51`	Severe persistent asthma with (acute) exacerbation	Higher severity asthma where monitored nebulized corticosteroid therapy may be indicated

Related CPT Codes

CPT Code	Description	Relationship to This Procedure
`94640`	Pressurized or non-pressurized inhalation treatment for acute airway obstruction or for sputum induction for diagnostic purposes (e.g., nebulizer, metered dose inhaler, DPI)	Commonly billed for the administration of nebulized medications like compounded budesonide when documenting the inhalation treatment session
`94620`	Pulmonary stress testing; spirometry, including graphic record, total and timed vital capacity, expiratory flow rate measurement(s), with interpretation and report	Performed before or during management to assess baseline lung function and response to therapy
`99213`	Office or other outpatient visit for the evaluation and management of an established patient, low to moderate complexity	Typical visit code for follow-up visits assessing response to nebulized budesonide
`96372`	Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular	Sometimes used for parenteral medication administration; included for workflow context though nebulized route uses `94640`
`99070`	Supplies and materials (except spectacles), used for patient care, not included in procedure codes or services; e.g., nebulizer supplies	Billed when additional consumable supplies for nebulizer administration are provided

OpenPayer

Summary & Overview